Innovative Medicines Canada welcomes Elaine Campbell as Interim President
Ottawa, June 7, 2016 – Innovative Medicines Canada is pleased to welcome Elaine Campbell as Interim President of the association, starting June 13, 2016.
Ms. Campbell brings with her 26 years of experience in the pharmaceutical sector, most recently as President and CEO of AstraZeneca Canada Inc., one of the world’s leading biopharmaceutical companies. This appointment afforded Ms. Campbell the opportunity to sit on Innovative Medicines Canada’s Board of Directors, where she worked closely with industry and association colleagues on improving the Canadian environment for the discovery, development and delivery of new medicines.
“On behalf of Innovative Medicines Canada’s Board of Directors, I would like to welcome Elaine Campbell to the team and thank her for coming on board to help steer the association through a period of exciting change,” said Michael Tremblay, Chair of Innovative Medicines Canada’s Board of Directors and President of Astellas Pharma Canada, Inc. “It’s great to be working with Elaine again, and her past experience and involvement with the association will be strong assets for us.”
Prior to her leadership role at AstraZeneca Canada Inc., Ms. Campbell held a number of senior leadership roles within the AstraZeneca US and Global businesses, including product development and commercialization roles, as well as overseeing multiple Global Marketing teams. She was previously a Vice President and member of the Business Operating Team with DuPont Pharmaceuticals. Her wealth of knowledge about the pharmaceutical discovery and development process will be assets to Innovative Medicines Canada as the association turns towards a renewed commitment to ensuring Canadians have timely and equitable access to new medicines.
Ms. Campbell holds a Bachelor of Applied Science in Chemical Engineering from the University of Toronto and a Master of Business Administration from St. Joseph’s University in Philadelphia. She has recently completed the ICD Directors Education Program in Toronto, in May 2016.
A search process will begin shortly to identify and appoint a permanent President for Innovative Medicines Canada.
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information:
Sarah Douglas, Media Relations